share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP:信函
美股SEC公告 ·  04/17 21:18

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.
Adial Pharmaceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-3, initially filed on April 12, 2024. The company seeks to have the registration become effective on April 19, 2024, at 5:00 p.m. Eastern Time, or as soon as possible thereafter. This request was communicated in a letter to the SEC, highlighting the company's acknowledgment of its obligations under federal securities laws regarding the issuance of securities covered by the statement. Adial Pharmaceuticals has designated Leslie Marlow and Hank Gracin of Blank Rome LLP with the authority to modify or withdraw the acceleration request if necessary.
Adial制药公司已正式要求美国证券交易委员会(SEC)加快其最初于2024年4月12日提交的S-3表格注册声明的生效日期。该公司力求使注册于美国东部时间2024年4月19日下午 5:00 生效,或此后尽快生效。该请求是在给美国证券交易委员会的一封信中传达的,信中强调了该公司承认其根据联邦证券法承担的有关该声明所涵盖证券发行的义务。Adial Pharmicals已指定Blank Rome LLP的莱斯利·马洛和汉克·格拉辛有权在必要时修改或撤回加速请求。
Adial制药公司已正式要求美国证券交易委员会(SEC)加快其最初于2024年4月12日提交的S-3表格注册声明的生效日期。该公司力求使注册于美国东部时间2024年4月19日下午 5:00 生效,或此后尽快生效。该请求是在给美国证券交易委员会的一封信中传达的,信中强调了该公司承认其根据联邦证券法承担的有关该声明所涵盖证券发行的义务。Adial Pharmicals已指定Blank Rome LLP的莱斯利·马洛和汉克·格拉辛有权在必要时修改或撤回加速请求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息